{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:22:21Z","timestamp":1770679341743,"version":"3.49.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.thromres.2018.01.003","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T07:38:09Z","timestamp":1524641889000},"page":"S23-S28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"S1","title":["Arterial thrombosis and cancer"],"prefix":"10.1016","volume":"164","author":[{"given":"Doron","family":"Aronson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2018.01.003_bb0005","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2018.01.003_bb0010","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1365-2141.2007.06973.x","article-title":"Common risk factors for both arterial and venous thrombosis","volume":"140","author":"Lowe","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0015","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(07)61745-0","article-title":"Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study","volume":"370","author":"S\u00f8rensen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2018.01.003_bb0020","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.01.003_bb0025","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.01.003_bb0030","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1002358","article-title":"A prospective natural-history study of coronary atherosclerosis","volume":"364","author":"Stone","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.01.003_bb0035","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Davi","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.01.003_bb0040","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2018.01.003_bb0045","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1136\/hrt.2009.175141","article-title":"Triggering of acute myocardial infarction: beyond the vulnerable plaque","volume":"96","author":"Newby","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.thromres.2018.01.003_bb0050","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.seminoncol.2014.04.009","article-title":"Platelets and cancer-associated thrombosis","volume":"41","author":"Connolly","year":"2014","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0055","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.seminoncol.2014.04.015","article-title":"Effects of cancer on platelets","volume":"41","author":"van Es","year":"2014","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0060","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2016.01.006","article-title":"Role of platelets in cancer and cancer-associated thrombosis: experimental and clinical evidences","volume":"139","author":"Mezouar","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2018.01.003_bb0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.disamonth.2016.03.003","article-title":"Cancer-associated thrombosis","volume":"62","author":"Fuentes","year":"2016","journal-title":"Dis. Mon."},{"key":"10.1016\/j.thromres.2018.01.003_bb0070","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2017-03-743211","article-title":"Cancer-associated pathways and biomarkers of venous thrombosis","volume":"130","author":"Hisada","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.01.003_bb0075","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2014-08-531582","article-title":"Platelets at the interface of thrombosis, inflammation, and cancer","volume":"126","author":"Franco","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.01.003_bb0080","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.thromres.2018.01.003_bb0085","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ctrv.2011.09.002","article-title":"Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications","volume":"38","author":"Soultati","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.thromres.2018.01.003_bb0090","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1470-2045(05)70207-2","article-title":"Cancer and venous thromboembolism","volume":"6","author":"Prandoni","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0095","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.thromres.2018.01.003_bb0100","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0105","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.01.003_bb0110","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.01.003_bb0115","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2006-01-0154","article-title":"Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis","volume":"108","author":"Zonder","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.01.003_bb0120","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.01.003_bb0125","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1161\/CIRCULATIONAHA.115.018351","article-title":"Cardiovascular complications of novel multiple myeloma treatments","volume":"133","author":"Li","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2018.01.003_bb0130","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1182\/blood-2014-01-547448","article-title":"The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2)","volume":"123","author":"Nayak","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.01.003_bb0135","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0140","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/annonc\/mdq702","article-title":"Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab","volume":"22","author":"Tebbutt","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0145","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/cncr.29169","article-title":"Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)","volume":"121","author":"Patel","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2018.01.003_bb0150","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.thromres.2018.01.003_bb0155","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdq587","article-title":"Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes","volume":"22","author":"Schutz","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0160","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20,000 patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.thromres.2018.01.003_bb0165","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0170","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1989.7.4.509","article-title":"Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study","volume":"7","author":"Rezkalla","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0175","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1","volume":"70","author":"Chang","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0180","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","article-title":"Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study","volume":"10","author":"de Forni","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ejhf.654","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"19","author":"Zamorano","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.thromres.2018.01.003_bb0190","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/annonc\/mdh150","article-title":"5-Fluorouracil induces arterial vasocontractions","volume":"15","author":"Sudhoff","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0195","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1200\/JCO.2008.17.1637","article-title":"Capecitabine-induced coronary vasospasm","volume":"26","author":"Goldsmith","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0200","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/j.ijcard.2013.12.274","article-title":"Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge?","volume":"172","author":"Rateesh","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0205","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/annonc\/mdu055","article-title":"Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk","volume":"25","author":"Lestuzzi","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0210","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/1097-0142(19880101)61:1<36::AID-CNCR2820610108>3.0.CO;2-6","article-title":"5-Fluorouracil-associated cardiotoxicity","volume":"61","author":"Freeman","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2018.01.003_bb0215","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/annonc\/mdf035","article-title":"Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil","volume":"13","author":"Frickhofen","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0220","first-page":"561","article-title":"The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits","volume":"9","author":"Cwikiel","year":"1995","journal-title":"Scanning Microsc."},{"key":"10.1016\/j.thromres.2018.01.003_bb0225","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3109\/02841869009091790","article-title":"Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil","volume":"29","author":"Eskilsson","year":"1990","journal-title":"Acta Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0230","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/sj.bjc.6600967","article-title":"Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity","volume":"88","author":"Cianci","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.thromres.2018.01.003_bb0235","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0002-9343(88)80268-7","article-title":"Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers","volume":"85","author":"Oleksowicz","year":"1988","journal-title":"Am. J. Med."},{"key":"10.1016\/j.thromres.2018.01.003_bb0240","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0245","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00277-017-3012-z","article-title":"Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios","volume":"96","author":"Saglio","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0250","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.01.003_bb0255","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/ejh.12367","article-title":"Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome","volume":"94","author":"Mirault","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0260","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.01.003_bb0265","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMp1313140","article-title":"Cancer-drug discovery and cardiovascular surveillance","volume":"369","author":"Groarke","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.01.003_bb0270","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/leu.2013.112","article-title":"Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.thromres.2018.01.003_bb0275","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1200\/JCO.2008.19.4274","article-title":"Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group","volume":"27","author":"Starling","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0280","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/annonc\/mdp597","article-title":"Myocardial infarction and other major vascular events during chemotherapy for testicular cancer","volume":"21","author":"Dieckmann","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0285","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0290","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2003.04.173","article-title":"Cardiovascular disease as a long-term complication of treatment for testicular cancer","volume":"21","author":"Huddart","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0295","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0300","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.3747\/co.v18i2.710","article-title":"Acute aortic thrombosis in patients receiving cisplatin-based chemotherapy","volume":"18","author":"Fernandes","year":"2011","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0305","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.urolonc.2014.11.012","article-title":"Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors","volume":"33","author":"Haugnes","year":"2015","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0310","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cjca.2015.12.023","article-title":"Vascular complications of cancer chemotherapy","volume":"32","author":"Cameron","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0315","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/eurheartj\/eht114","article-title":"Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease","volume":"35","author":"Groarke","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2018.01.003_bb0320","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2214\/AJR.07.3112","article-title":"Coronary artery disease after radiation therapy for Hodgkin's lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients","volume":"191","author":"Rademaker","year":"2008","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0325","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijrobp.2007.12.058","article-title":"Cardiac dose from tangential breast cancer radiotherapy in the year 2006","volume":"72","author":"Taylor","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.thromres.2018.01.003_bb0330","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1200\/JCO.2011.34.5900","article-title":"Distribution of coronary artery stenosis after radiation for breast cancer","volume":"30","author":"Nilsson","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0335","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0340","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/jnci\/djk029","article-title":"Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study","volume":"99","author":"Swerdlow","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.thromres.2018.01.003_bb0345","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.thromres.2018.01.003_bb0350","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.01.003_bb0355","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.01.003_bb0360","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005633","article-title":"Long-term cardiovascular risk after radiotherapy in women with breast cancer","volume":"6","author":"Cheng","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.thromres.2018.01.003_bb0365","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1055\/s-0035-1564040","article-title":"Cancer tissue procoagulant mechanisms and the hypercoagulable state of patients with cancer","volume":"41","author":"Falanga","year":"2015","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2018.01.003_bb0370","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F","volume":"33","author":"Tefferi","year":"2007","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2018.01.003_bb0375","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0034-1370794","article-title":"Thrombosis in myeloproliferative neoplasms","volume":"40","author":"Falanga","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2018.01.003_bb0380","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/asheducation.V2012.1.571.3798557","article-title":"Thrombotic disease in the myeloproliferative neoplasms","volume":"2012","author":"Falanga","year":"2012","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.thromres.2018.01.003_bb0385","first-page":"178","article-title":"Prevention and management of thrombosis in myeloproliferative neoplasms","volume":"15","author":"Sekhar","year":"2017","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.thromres.2018.01.003_bb0390","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.01.003_bb0395","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.01.003_bb0400","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.01.003_bb0405","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2018.01.003_bb0410","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.01.003_bb0415","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.01.003_bb0420","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.leu.2404377","article-title":"Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features","volume":"21","author":"Breccia","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.thromres.2018.01.003_bb0425","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0140-6736(93)91315-D","article-title":"Multiple thrombosis in acute promyelocytic leukaemia after tretinoin","volume":"342","author":"de Lacerda","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2018.01.003_bb0430","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.V79.2.534.534","article-title":"All-trans retinoic acid: not only a differentiating agent, but also an inducer of thromboembolic events in patients with M3 leukemia","volume":"79","author":"Runde","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.01.003_bb0435","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.thromres.2012.11.024","article-title":"Thrombosis in acute promyelocytic leukemia","volume":"131","author":"Rashidi","year":"2013","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2018.01.003_bb0440","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.2147\/OTT.S103735","article-title":"Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review","volume":"9","author":"Zhang","year":"2016","journal-title":"Onco Targets Ther."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2018.01.003_bb0445","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S0049-3848(16)30103-7","article-title":"Update of thrombosis in multiple myeloma","volume":"140","author":"Leebeek","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2018.01.003_bb0450","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2013.06.010","article-title":"Ionizing radiation and atherosclerosis: current knowledge and future challenges","volume":"230","author":"Borghini","year":"2013","journal-title":"Atherosclerosis"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818300033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818300033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T21:36:20Z","timestamp":1571261780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384818300033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":90,"alternative-id":["S0049384818300033"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2018.01.003","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arterial thrombosis and cancer","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2018.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}